We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| International Biotechnology Trust Plc | LSE:IBT | London | Ordinary Share | GB0004559349 | ORD 25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -4.00 | -0.67% | 590.00 | 36,316 | 16:35:07 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 592.00 | 598.00 | 596.00 | 594.00 | 596.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | 44.54M | 38.88M | 1.1129 | 5.34 | 207.51M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:14 | AT | 19 | 590.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/6/2025 | 10:45 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 19/6/2025 | 10:40 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 18/6/2025 | 11:24 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 17/6/2025 | 10:11 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 16/6/2025 | 10:25 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 13/6/2025 | 11:55 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 12/6/2025 | 11:31 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 12/6/2025 | 09:15 | ALNC |  Best and worst performing London-listed funds in May - QuotedData |
| 11/6/2025 | 10:27 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
| 10/6/2025 | 13:11 | UK RNS | Intl. Biotechnology Trust PLC Net Asset Value(s) |
International Biotechnol... (IBT) Share Charts1 Year International Biotechnol... Chart |
|
1 Month International Biotechnol... Chart |
Intraday International Biotechnol... Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/5/2025 | 15:41 | International Biotechnolgy Trust | 408 |
| 29/4/2019 | 10:54 | International Boitechnology Trust | 148 |
| 21/10/2001 | 04:31 | "Biotech names selling on air" | 2 |
| 28/12/2000 | 12:08 | Soros buys Int.Biotech stake | 5 |
| 17/7/2000 | 18:11 | Int Biotech | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-06-20 15:35:14 | 590.00 | 19 | 112.10 | AT |
| 2025-06-20 15:35:14 | 590.00 | 153 | 902.70 | AT |
| 2025-06-20 15:35:14 | 590.00 | 153 | 902.70 | AT |
| 2025-06-20 15:35:14 | 590.00 | 153 | 902.70 | AT |
| 2025-06-20 15:35:14 | 590.00 | 153 | 902.70 | AT |
| Top Posts |
|---|
Posted at 21/6/2025 09:20 by International Biotechnol... Daily Update International Biotechnology Trust Plc is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker IBT. The last closing price for International Biotechnol... was 594p.International Biotechnol... currently has 34,933,700 shares in issue. The market capitalisation of International Biotechnol... is £207,506,178. International Biotechnol... has a price to earnings ratio (PE ratio) of 5.34. This morning IBT shares opened at 596p |
Posted at 13/5/2025 11:34 by bmcollins But not so good to see its Trump inspired share price plumb new depths... |
Posted at 13/5/2025 11:13 by speedsgh Good to see IBT outperforming its reference index in H1...Half-year Report - |
Posted at 20/1/2025 13:04 by speedsgh Virtual Outlook Presentation - IBT is pleased to announce that portfolio managers Ailsa Craig and Marek Poszepczynski will be holding a live presentation on the outlook for the biotechnology sector in 2025, to be held virtually at 09:00 on Tuesday 28 January 2025. The presentation is open to all audiences. Questions can be submitted to the portfolio managers throughout the event. Please register for the session by the following link: |
Posted at 14/1/2025 16:39 by speedsgh Following today's news the IBT NAV has increased from 752.95p to 775.82p (cum income) leaving it trading on ca. 10% discount. |
Posted at 01/1/2025 14:37 by c3479z1 it's all personal preference,on the other hand, I support the approach of not taking on the binary risk when trial results are about to be announced. eg Novo, the giant Danish announced marginally below expectations results for cagrisema in December and plunged 20%, had the result been above then a pop of similar magnitude might have happened. see also Vertex result on suzetrigine. Had a smaller biotech announced a marginally below result in their pipeline drug, the reaction might have been even more severe or a zero. IBT has a good record and spreads the money widely in a volatile sector. |
Posted at 04/7/2024 10:09 by speedsgh Dividend Declaration - At the Annual General Meeting of International Biotechnology Trust plc (the "Company") held on 12 December 2023, shareholders approved the Company's dividend policy of making dividend payments, equivalent to 4% of the Company's net asset value as at the last day of the preceding financial year (31 August 2023), through two equal semi-annual distributions. In accordance with this policy, the first interim dividend for the period ending 31 August 2024 was paid on 26 January 2024. The Directors have today declared the payment of a second interim dividend of 14.5 pence per ordinary share for the year ending 31 August 2024. Ex-dividend date: 25 July 2024 Record date: 26 July 2024 Payment date: 23 August 2024 Dividend per share: 14.5 pence |
Posted at 02/5/2024 09:46 by speedsgh IBT is one of three trusts (alongside RTW & BIOG) highlighted as 'appealing opportunities' in the following piece...Charlotte Cuthbertson: MIGO’s positioning for the biotech recovery - The co-manager of MIGO Opportunities Trust says that increased M&A, interest rate cuts, rising drug approvals and robust innovation will drive the biotech bounce-back higher... |
Posted at 12/4/2024 13:44 by melloteam FREE EVENTIBT will be presenting on the Mello Investment Trusts and Funds event on Tuesday 23rd April 2024 at 1pm The programme is as follows: 1:00pm Emma Bird, Head of Investment Trust Research, Winterflood Securities 1:30pm Company presentation by JPMorgan Asia Growth & Income plc 2:00pm Company presentation by Literacy Capital 2:30pm Company presentation by International Biotechnology Trust 3:00pm Investment Trusts and Funds Panel For more information, click here: To join for free, register for the webinar here: |
Posted at 27/2/2024 11:08 by affemoose Anyone watching the CityWIre IBT presentation that's on now? |
Posted at 03/8/2023 13:02 by speedsgh Appointment of New Fund Manager - · Schroders selected as IBT's Fund Manager and Alternative Investment Fund Manager · Continuity of investment approach and dividend policy · Ailsa Craig and Marek Poszepczynski to continue as the Company's portfolio managers The Board of IBT is pleased to announce that it has decided to appoint Schroder Unit Trusts Ltd ("Schroders") as the Company's Fund Manager and Alternative Investment Fund Manager ("AIFM") with a mandate to continue IBT's investment policy, which offers access to the fast-growing biotechnology sector through an actively managed, diversified strategy. This appointment is consistent with the feedback received from shareholders, which endorsed the continuity of the Company's investment approach under the existing investment management team and retaining the dividend policy. As such, the Board believes that Schroders' appointment will deliver positive long-term benefits for IBT and its shareholders. Ailsa Craig and Marek Poszepczynski have accepted Schroders' conditional offer for them to continue as the Company's portfolio managers. Ailsa and Marek took on the position of IBT's Joint Lead Managers in March 2021, having been involved in managing IBT since 2006 and 2013 respectively. The Company's net asset value ("NAV") has outperformed its benchmark, the Nasdaq Biotechnology Index, by 6.7% since March 2021 and by 9.0% and 35.5% respectively over the last five and ten years(1). Schroders will provide a platform from which IBT can continue to deliver its differentiated proposition of solid relative returns with lower volatility, and an annual dividend of 4% of NAV(2). There are also no plans to change the Company's discount and premium management policy. These appointments are subject to finalisation of legal documentation and to regulatory approval, and IBT is expected to transition formally to Schroders in November 2023, following publication of the Company's annual results to 31 August 2023. IBT will continue to have a relationship with SV Health Managers LLP ("SV Health Investors") in connection with the existing unquoted portfolio, which is principally invested in two SV Health Investors funds. The Company has consulted with a number of its major shareholders who have indicated their support for the Board's process. In accordance with the Company's articles of association, which provide for a continuation vote every two years, a continuation resolution will be proposed at the Company's December 2023 Annual General Meeting. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
